Clinical implementation of pre-treatment DPYD genotyping in capecitabine-treated metastatic breast cancer patients

PURPOSE: Metastatic breast cancer (mBC) patients with DPYD genetic variants linked to loss of dihydropyrimidine dehydrogenase (DPD) activity are at risk of severe capecitabine-associated toxicities. However, prospective DPYD genotyping has not yet been implemented in routine clinical practice. Follo...

Descripción completa

Detalles Bibliográficos
Autores principales: Stavraka, Chara, Pouptsis, Athanasios, Okonta, Leroy, DeSouza, Karen, Charlton, Philip, Kapiris, Matthaios, Marinaki, Anthony, Karapanagiotou, Eleni, Papadatos-Pastos, Dionysis, Mansi, Janine
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2019
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533219/
https://www.ncbi.nlm.nih.gov/pubmed/30746637
http://dx.doi.org/10.1007/s10549-019-05144-9

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6533219/
https://www.ncbi.nlm.nih.gov/pubmed/30746637
http://dx.doi.org/10.1007/s10549-019-05144-9

Ejemplares similares